The Global Fund describes the $41.6 million in funding awarded to India in April as an innovative approach that will catalyze significant additional funding for the fight against tuberculosis. The award includes $40.0 million to buy down a portion of a $400.0-million loan from the World Bank over five years.
CSOs in India and the Asia-Pacific region focus on the preparatory meeting for the Global Fund’s Sixth Replenishment
The preparatory meeting for the Global Fund’s Sixth Replenishment, which is scheduled for 7–8 February 2019 in New Delhi, is the first such meeting to be held in an implementing country.
The Global Fund announced on its website on 5 September that India will host the preparatory meeting for the Sixth Replenishment in New Delhi, on 8 February 2019.
The purpose of the preparatory meeting is “to provide Global Fund partners with key information on the impact to be achieved and the financial resources needed to end the epidemics by 2030, in line with the Sustainable Development Goals,” the Fund says.
In the beginning, there was performance-based funding. It was the outcomes-based mechanism of choice for the Global Fund and forms the foundation on which the Global Fund’s grant architecture was built. The idea was simple. Release funding in tranches, whereby recipients were required to reach specific targets before the rest of the grant would be disbursed.
Among the grants approved by the Board recently were four TB grants and one TB/HIV grant to India. In this article, we report on the comments from the Technical Review Panel (TRP) and the Grants Approvals Committee (GAC) on the funding request from which these grants emanated.
The Secretariat has reported on developments concerning incentive funding awarded to Nigeria and India as part of the 2014-2016 allocations. The updates were contained in the latest report of the Grant Approvals Committee to the Board.
Between 29 March and 13 April 2016, the Office of the Inspector General published reports on three investigations – one each in India, Guyana and Bangladesh. The OIG identified non-compliant expenditures ranging from $56,966 for a malaria grant in Guyana to $311,637 for a TB grant in Bangladesh. This article provides a brief summary of the OIG’s findings.
Given India’s economic status, the government should assume greater responsibility for TB programmes, and should ultimately assume full responsibility.
Major improvements are needed in the management and implementation of Global Fund grants in India. This is the main conclusion of an audit of 10 grants to India undertaken by the Office of the Inspector General (OIG).